Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.390
+0.120 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
July 23, 2021
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,
Via
Benzinga
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks
July 15, 2021
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing...
Via
Talk Markets
Exposures
COVID-19
Psychedelic Decriminalization Creating Market Opportunities
July 12, 2021
Via
FinancialNewsMedia
Topics
Cannabis
Law Enforcement
Exposures
Cannabis
Legal
How To Invest In "Magic Mushrooms" (Psychedelics)
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar...
Via
Benzinga
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
July 07, 2021
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D...
Via
Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
July 07, 2021
Via
FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
July 02, 2021
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...
Via
Benzinga
Understanding Compass Pathways's Unusual Options Activity
July 01, 2021
On Thursday, shares of Compass Pathways (NASDAQ:CMPS) saw unusual options activity. After the option alert, the stock price moved up to $38.2. Sentiment: NEUTRAL Option Type:...
Via
Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
June 30, 2021
Institutional analysts are taking a liking to the industry ...
Via
Benzinga
3 Top Psychedelic Stocks to Buy Now
June 30, 2021
These companies developing hallucinogens have more than meets the eye.
Via
The Motley Fool
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study
June 29, 2021
Compass Pathways (NASDAQ:CMPS), a biotech company in the p...
Via
Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
June 28, 2021
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa...
Via
Benzinga
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
June 28, 2021
Upgrades For Toll Brothers Inc (NYSE:
Via
Benzinga
Atai IPO Day An Underwhelming Event
June 21, 2021
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
June 21, 2021
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
June 18, 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...
Via
Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
June 18, 2021
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO.
Via
Investor's Business Daily
Topics
Initial Public Offering
Exposures
Securities Market
Is ATAI Stock A Buy After The IPO?
June 16, 2021
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock.
Via
Talk Markets
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
June 09, 2021
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said.
Via
Investor's Business Daily
What Do You Really Know About Psychedelics And Psychedelics Stocks?
June 08, 2021
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That...
Via
Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
June 08, 2021
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
June 07, 2021
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ...
Via
Benzinga
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
June 02, 2021
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at...
Via
Talk Markets
Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria
May 28, 2021
As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producin...
Via
Benzinga
Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week
May 27, 2021
Welcome to the Cannabis...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
May 27, 2021
Welcome to the Cannabis...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
How Risky Are Psychedelic Stocks?
May 26, 2021
Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Is Compass Pathways a Buy?
May 25, 2021
The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker?
Via
The Motley Fool
Topics
Cannabis
Law Enforcement
Exposures
Cannabis
Legal
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.